International Journal of Medicine and Health Development

REVIEW ARTICLE
Year
: 2022  |  Volume : 27  |  Issue : 2  |  Page : 109--113

N-nitrosodimethylamine (NDMA) and some prescribed medicines: A mini-review


Chidiebere V Ugwueze1, Chidiebele M Ezeude2, Chinweuba M Abonyi3, Chidimma B Nwatu4, Kingsley N Ukwaja1, Ekenechukwu E Young4 
1 Department of Internal Medicine, Alex Ekwueme Federal Teaching Hospital, Abakaliki, Ebonyi State, Nigeria
2 Department of Medicine, Nnamdi Azikiwe University Teaching Hospital, Nnewi, Anambra State, Nigeria
3 Department of Medicine, Enugu State University Teaching Hospital, Enugu, Nigeria
4 Department of Medicine, University of Nigeria Teaching Hospital, Enugu, Nigeria

Correspondence Address:
Chidiebere V Ugwueze
Department of Internal Medicine, Alex Ekwueme Federal Teaching Hospital, Abakaliki, Ebonyi State.
Nigeria

Recently, there have been notices of drug recalls by different pharmaceutical companies. This is based on the finding of high level of N-nitrosodimethylamine (NDMA) in such medications. These medications are useful in the management of some diseases which affect a significant percentage of the population. It is therefore necessary to evaluate the chemical substance (NDMA), the sources, mechanisms, and the effects it can pose on the users of implicated medications. It is also important to consider the possible ways to avert the entry of NDMA into the medications. The substance, NDMA, has been found to be present as an impurity in high concentration in certain drugs, especially metformin slow release, valsartan and ranitidine. The approved healthy daily intake of NDMA by Food and Drug Administration (FDA) is about 96 ng. However, the concentrations of NDMA found in these drugs were exceptionally high which led to their recall. The high level of NDMA may arise from contamination, direct synthetic process, or from the degradation process of the medicine. Chromatography is the best detection modality of NDMA. The carcinogenic risk is the most feared effect of accumulated NDMA beyond the acceptable limit. On the basis of the frequent recalls of these medications, it is therefore imperative that pharmacists, pharmacologists, and physicians are acquainted with the sources of NDMA. This is in view of the serious risk it can pose to patients’ safety and quality of life. These concerns have given rise to this review article.


How to cite this article:
Ugwueze CV, Ezeude CM, Abonyi CM, Nwatu CB, Ukwaja KN, Young EE. N-nitrosodimethylamine (NDMA) and some prescribed medicines: A mini-review.Int J Med Health Dev 2022;27:109-113


How to cite this URL:
Ugwueze CV, Ezeude CM, Abonyi CM, Nwatu CB, Ukwaja KN, Young EE. N-nitrosodimethylamine (NDMA) and some prescribed medicines: A mini-review. Int J Med Health Dev [serial online] 2022 [cited 2022 Jul 7 ];27:109-113
Available from: https://www.ijmhdev.com/article.asp?issn=2635-3695;year=2022;volume=27;issue=2;spage=109;epage=113;aulast=Ugwueze;type=0